Immunocore is a biotechnology company that specializes in the development of novel cancer therapies. The company's proprietary technology platform, called ImmTACs, is designed to activate the immune system to target and destroy cancer cells. Immunocore's lead product candidate, IMCgp100, is currently in clinical trials for the treatment of melanoma and other solid tumors. The company was founded in 2008 and is headquartered in Abingdon, UK.